Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$55.06 - $69.99 $201,354 - $255,953
3,657 New
3,657 $205,000
Q1 2023

May 15, 2023

SELL
$43.42 - $57.37 $1.11 Million - $1.46 Million
-25,457 Reduced 78.54%
6,955 $335,000
Q4 2022

Feb 14, 2023

BUY
$38.8 - $55.46 $1.26 Million - $1.8 Million
32,412 New
32,412 $1.62 Million
Q2 2022

Aug 15, 2022

BUY
$33.54 - $55.0 $132,717 - $217,635
3,957 New
3,957 $215,000
Q1 2022

May 18, 2022

SELL
$31.02 - $48.18 $4.22 Million - $6.56 Million
-136,132 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$41.14 - $56.98 $226,270 - $313,390
5,500 Added 4.21%
136,132 $6.35 Million
Q2 2021

Aug 16, 2021

BUY
$25.8 - $41.09 $3.37 Million - $5.37 Million
130,632 New
130,632 $5.33 Million
Q1 2021

May 17, 2021

SELL
$23.55 - $32.4 $3.08 Million - $4.23 Million
-130,632 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$25.8 - $32.39 $1,161 - $1,457
-45 Reduced 0.03%
130,632 $3.85 Million
Q3 2020

Nov 12, 2020

BUY
$27.5 - $39.61 $3.59 Million - $5.18 Million
130,677 New
130,677 $4.04 Million

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $6.73B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Nomura Holdings Inc Portfolio

Follow Nomura Holdings Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nomura Holdings Inc, based on Form 13F filings with the SEC.

News

Stay updated on Nomura Holdings Inc with notifications on news.